Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies
Polyrizon (PLRZ) has announced the publication of a national phase patent application by the USPTO for its intranasal hydrogel technologies. The patent application covers two core platforms: Capture and Contain (C&C™) and Trap and Target (T&T™).
The C&C™ platform features a natural 3D polymeric network that adheres to nasal mucosa, creating a physical barrier against airborne biological threats like allergens, viruses, and molds. The T&T™ platform is designed for enhanced drug delivery, offering prolonged residence time and close mucosal contact for improved therapeutic efficacy. The technology can be customized for various molecules and medical applications.
Polyrizon (PLRZ) ha annunciato la pubblicazione di una domanda di brevetto per la fase nazionale da parte dell'USPTO per le sue tecnologie idrogel intranasali. La domanda di brevetto copre due piattaforme core: Capture and Contain (C&C™) e Trap and Target (T&T™).
La piattaforma C&C™ presenta una rete polimerica naturale in 3D che aderisce alla mucosa nasale, creando una barriera fisica contro minacce biologiche aeree come allergeni, virus e muffe. La piattaforma T&T™ è progettata per una somministrazione dei farmaci migliorata, offrendo un tempo di permanenza prolungato e un contatto ravvicinato con la mucosa per un'efficacia terapeutica migliorata. La tecnologia può essere personalizzata per diverse molecole e applicazioni mediche.
Polyrizon (PLRZ) ha anunciado la publicación de una solicitud de patente para la fase nacional por parte del USPTO para sus tecnologías de hidrogel intranasal. La solicitud de patente cubre dos plataformas principales: Capture and Contain (C&C™) y Trap and Target (T&T™).
La plataforma C&C™ cuenta con una red polimérica natural en 3D que se adhiere a la mucosa nasal, creando una barrera física contra amenazas biológicas en el aire como alérgenos, virus y mohos. La plataforma T&T™ está diseñada para mejorar la entrega de medicamentos, ofreciendo un tiempo de residencia prolongado y un contacto cercano con la mucosa para una mejor eficacia terapéutica. La tecnología se puede personalizar para diversas moléculas y aplicaciones médicas.
폴리리존 (PLRZ)는 미국 특허청(USPTO)에 의해 비강용 하이드로겔 기술에 대한 국가 단계 특허 출원 발표를 했습니다. 이 특허 출원은 두 가지 핵심 플랫폼을 포함합니다: Capture and Contain (C&C™) 및 Trap and Target (T&T™).
C&C™ 플랫폼은 비강 점막에 부착되는 자연 3D 폴리머 네트워크로, 알레르기 유발 물질, 바이러스 및 곰팡이와 같은 공기 중 생물학적 위협에 대한 물리적 장벽을 생성합니다. T&T™ 플랫폼은 향상된 약물 전달을 위해 설계되었으며, 장기간의 체류 시간과 점막에 가까운 접촉을 제공하여 치료 효능을 향상시킵니다. 이 기술은 다양한 분자 및 의료 응용을 위해 맞춤 설정할 수 있습니다.
Polyrizon (PLRZ) a annoncé la publication d'une demande de brevet pour la phase nationale par l'USPTO pour ses technologies de gel intranasal. La demande de brevet couvre deux plateformes principales : Capture and Contain (C&C™) et Trap and Target (T&T™).
La plateforme C&C™ dispose d'un réseau polymérique naturel en 3D qui adhère à la muqueuse nasale, créant une barrière physique contre les menaces biologiques en suspension dans l'air telles que les allergènes, les virus et les moisissures. La plateforme T&T™ est conçue pour améliorer l'administration des médicaments, offrant un temps de résidence prolongé et un contact étroit avec la muqueuse pour une efficacité thérapeutique accrue. La technologie peut être personnalisée pour diverses molécules et applications médicales.
Polyrizon (PLRZ) hat die Veröffentlichung eines nationalen Patentantrags beim USPTO für seine intranasalen Hydrogelsysteme angekündigt. Der Patentantrag umfasst zwei Kernplattformen: Capture and Contain (C&C™) und Trap and Target (T&T™).
Die C&C™-Plattform verfügt über ein natürliches 3D-polymernetzwerk, das an der Nasenschleimhaut haften bleibt und eine physische Barriere gegen luftgetragene biologische Bedrohungen wie Allergene, Viren und Schimmel bildet. Die T&T™-Plattform ist für eine verbesserte Arzneimittelabgabe konzipiert und bietet eine verlängerte Verweildauer sowie engen Kontakt mit der Schleimhaut zur Verbesserung der therapeutischen Wirksamkeit. Die Technologie kann für verschiedene Moleküle und medizinische Anwendungen angepasst werden.
- Patent application publication strengthens intellectual property protection
- Dual platform technology addressing both protective and therapeutic applications
- Customizable drug delivery system enabling multiple medical applications
- Company still in development stage with no commercialized products
- No mention of timeline for patent approval or commercialization
Insights
The publication of a national phase patent application represents a strategic milestone for Polyrizon's IP portfolio, particularly for their C&C™ and T&T™ platforms. However, this is merely the beginning of a lengthy examination process that typically takes 2-3 years before potential patent issuance. The application's publication doesn't guarantee patent approval and the scope of any granted claims may be significantly narrower than what's initially filed.
The dual-platform approach targeting both protective barriers (C&C™) and drug delivery (T&T™) within a single patent application is noteworthy, as it could provide broad market exclusivity if granted. However, the nasal drug delivery space is heavily patented, which may present challenges during prosecution. The emphasis on the natural 3D polymeric network could be a distinguishing factor for patentability.
The technical aspects of Polyrizon's platforms show promise in addressing two distinct market needs: protective barriers and drug delivery. The C&C™ platform's ability to form physical barriers against multiple threats (allergens, viruses, molds) suggests versatility in potential applications. The T&T™ platform's focus on prolonged residence time could offer advantages over existing nasal delivery systems, particularly for drugs requiring sustained release.
In simpler terms, imagine having a smart protective mesh in your nose that can either catch harmful particles (like a sophisticated face mask) or slowly release medicine exactly where needed (like a time-release capsule). While innovative, the commercial success will ultimately depend on clinical validation and regulatory approval, neither of which is addressed in this patent news.
For investors, while patent protection is important for biotech companies, this early-stage IP development alone doesn't significantly impact near-term value. The company still needs to demonstrate clinical efficacy and safety through trials.
Raanana, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the publication of a national phase patent application by the United States Patent and Trademark Office (“USPTO”). The patent application encompasses key aspects of Polyrizon's two core platform technologies: Capture and Contain (C&C™), a nasal blocker technology, and Trap and Target (T&T™), designed for advanced nasal drug delivery. Both technologies represent Polyrizon's commitment to creating innovative solutions for protecting and treating via the nasal cavity.
Polyrizon Technologies: Advanced Drug Delivery and Protection Platforms
Polyrizon’s innovative Capture and Contain (C&C™) platform utilizes a natural 3D polymeric network engineered to adhere optimally to the nasal mucosa. This advanced network forms a physical barrier that captures and contains airborne biological threats, such as allergens, viruses, and molds, preventing their penetration and protecting the body.
In addition, Polyrizon’s T&T platform is a novel drug delivery system designed for prolonged residence time and close contact with mucosal tissues, ensuring highly effective and targeted delivery of medications. Developed by drug delivery experts, the T&T platform can be customized to meet the unique requirements of different molecules, enhancing therapeutic efficacy and enabling a wide range of medical applications.
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its commitment to creating innovative solutions for protecting and treating via the nasal cavity. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s prospectus (Registration No. 333-266745), dated October 24, 2024 and filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
FAQ
What technologies are covered in PLRZ's USPTO patent application?
How does Polyrizon's C&C™ nasal blocker technology work?
What is the purpose of PLRZ's T&T™ platform technology?
What advantages does PLRZ's T&T™ drug delivery system offer?
